Cal,...
Yes she responded by saying some of the issues dealt with labelling,...and that the HC idiots should have seen that the documentation provided by DMX answered all their other concerns. But she wasn't specific,..which I as an investor would want her to be. Even a complex problem can be summarized quickly and succinctly by a smart person like REK, and she had to know the question was coming. So I assume she didn't want to answer it directly because it may reflect poorly on the drug, whether HC is right or not.
Now HC is there to protect the consumer from drugs that may hurt us and/or provide no benefit. They have degrees, experience, and their own viewpoint. They have access to the medical profession and researchers.
So we are left to chose who we should believe, HC or REK. I don't know who to believe, but given what is happening with other drug companies and companies in general, we know companies will emphasize the positive, try and make us ignore the negative. QLT, Biovail, ImClone, Elan, Enron, Nortel, Internet, Tech, etc., etc.
Wouldn't it be nice to have HC's viewpoint?,...there is a groundswell of support to make communications between companies and the FDA open to public scrutiny, especially after ImClone.
There may be absolutely nothing wrong except for the bumbling incompetence of HC investigators as popularized by REK and this thread of pro shareholders. Or,.....
PS,..maybe you are right about the pot thing. Maybe they should prescribe it to suffering DMX shareholders to ease the pain of the latest slap in the face (ggggggggg) |
